In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Individuals will obtain treatment till ailment progression or perhaps the individuals are not able to tolerate the study drugs. 88 These preclinical studies offer paradigms for long term clinical trials in https://isabbv-744effectiveforhem46891.creacionblog.com/31935051/details-fiction-and-clinical-effectiveness-of-abbv-744-in-aml-patients